Wedbush Reduces Earnings Estimates for Larimar Therapeutics

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Investment analysts at Wedbush decreased their Q1 2025 earnings per share estimates for shares of Larimar Therapeutics in a report released on Monday, March 24th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.39) per share for the quarter, down from their previous estimate of ($0.25). The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics' Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.52) EPS, FY2026 earnings at ($1.73) EPS and FY2027 earnings at ($1.17) EPS.

Other analysts have also recently issued reports about the stock. Robert W. Baird dropped their price objective on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a report on Tuesday, March 25th. Guggenheim reiterated a "buy" rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Truist Financial began coverage on Larimar Therapeutics in a research note on Wednesday, January 29th. They issued a "buy" rating and a $18.00 target price for the company. Finally, HC Wainwright lifted their price target on Larimar Therapeutics from $15.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday, March 25th. Eleven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $20.22.

Remove Ads

Larimar Therapeutics Price Performance

Shares of LRMR traded down $0.05 during trading hours on Wednesday, hitting $2.35. The stock had a trading volume of 986,346 shares, compared to its average volume of 645,138. The stock has a market capitalization of $149.95 million, a price-to-earnings ratio of -2.04 and a beta of 0.99. The company's fifty day moving average is $3.08 and its two-hundred day moving average is $5.10. Larimar Therapeutics has a 52 week low of $2.19 and a 52 week high of $11.20.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

Institutional Investors Weigh In On Larimar Therapeutics

Several large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in Larimar Therapeutics during the fourth quarter worth about $25,000. Algert Global LLC acquired a new position in Larimar Therapeutics in the 4th quarter worth $47,000. China Universal Asset Management Co. Ltd. acquired a new position in Larimar Therapeutics in the 4th quarter worth $52,000. Graham Capital Management L.P. bought a new position in Larimar Therapeutics during the 4th quarter worth about $54,000. Finally, ProShare Advisors LLC bought a new stake in shares of Larimar Therapeutics in the fourth quarter valued at about $58,000. Institutional investors own 91.92% of the company's stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.